Post-Approval Vascular Access Study for Dialysis Patients Using EndoForce Technology

This comprehensive observational study focuses on evaluating the long-term safety and effectiveness of the EndoForce Connector System in patients with end-stage renal disease (ESRD) who require hemodialysis. The research will follow 150 adult participants for two years to assess how well this innovative vascular access technology performs in real-world clinical settings after receiving regulatory approval.

Understanding the importance of vascular access is crucial for dialysis patients and their caregivers. Hemodialysis requires reliable access to blood vessels, typically through an arteriovenous graft (AVG). The EndoForce Connector System represents an advanced approach to creating these vital connections using endovascular techniques, which may offer benefits over traditional surgical methods. This study aims to provide valuable data on how this technology performs over an extended period, giving patients and healthcare providers better information to make treatment decisions.

The study includes comprehensive safety monitoring that will track all device-related events, including serious complications that might require hospitalization, additional procedures, or other interventions. Researchers will specifically watch for issues like device migration, sealing problems, leakage, infections, bleeding complications, and pseudoaneurysms. This thorough safety assessment ensures that any potential concerns with the technology are identified and understood.

Beyond safety, the research will measure several key performance indicators including:

• Cumulative patency rates - how long the access remains functional without complete failure
• Primary patency - time until the first clotting event or procedure needed to maintain access
• Number of interventions required to keep the access working properly
• Immediate procedure success measured by adequate blood flow through the graft

For patients considering participation, the eligibility criteria include being at least 18 years old, having ESRD requiring hemodialysis, ability to have the graft placed in the upper arm, and willingness to comply with the study requirements and follow-up schedule. The study excludes pregnant patients and those participating in other investigational studies without approval.

The significance of research in nephrology and vascular access cannot be overstated. For the millions of people worldwide living with end-stage renal disease, reliable vascular access represents literally a lifeline - without functioning access, they cannot receive the dialysis treatments that keep them alive. Each year, vascular access complications account for substantial morbidity, hospitalization costs, and decreased quality of life for dialysis patients. Studies like this one contribute to the ongoing improvement of dialysis care by evaluating new technologies that may reduce complications, improve longevity of access sites, and ultimately enhance patient outcomes and quality of life. The post-approval nature of this study is particularly important as it examines how the technology performs outside the controlled environment of initial clinical trials, providing real-world evidence that can guide clinical practice and future innovations in renal care.